SCHEDULE: Paradigm BioCapital Discloses Janux Therapeutics Stake
Beneficial Ownership Report
Paradigm BioCapital Advisors LP and related entities reported a 4.9% beneficial ownership stake in Janux Therapeutics, Inc. common stock.
Summary
- Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively reported beneficial ownership of 2,920,258 shares of Janux Therapeutics, Inc. common stock.
- This aggregate ownership represents 4.9% of Janux Therapeutics' outstanding common stock.
- Paradigm BioCapital International Fund Ltd. separately reported beneficial ownership of 2,593,376 shares, representing 4.4% of the common stock.
- The percentages are based on 59,175,157 shares of Common Stock outstanding as of May 6, 2025, as reported in Janux Therapeutics' Form 10-Q filed on May 8, 2025.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative operational performance or outlook for the company. It simply reports a significant institutional stake.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment firm, Paradigm BioCapital, has taken a notable stake in Janux Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector as institutional investors often take positions in companies with promising drug pipelines or technologies.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor's stake can influence market perception and potentially provide a signal of institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-05-06 | Date as of which 59,175,157 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-05-08 | Date Janux Therapeutics' Form 10-Q was filed with the SEC, reporting outstanding shares. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G. |
| 2025-08-14 | Date the Schedule 13G was signed and filed. |
Keywords
Janux Therapeutics, Paradigm BioCapital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.